Suzhou Zelgen Biopharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.54%

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has an Asset Resilience Ratio of 0.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥16.20 Million

≈ $2.37 Million USD Cash + Short-term Investments

Total Assets

CN¥3.01 Billion

≈ $440.95 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Check Suzhou Zelgen Biopharmaceuticals Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Suzhou Zelgen Biopharmaceuticals Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥16.20 Million	0.54%
Total Liquid Assets	CN¥16.20 Million	0.54%

Asset Resilience Insights

Limited Liquidity: Suzhou Zelgen Biopharmaceuticals Co Ltd maintains only 0.54% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Suzhou Zelgen Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Suzhou Zelgen Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Prostemics Co. Ltd KQ:203690	Biotechnology	0.31%
ORUM KQ:475830	Biotechnology	82.74%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
TG Therapeutics Inc NASDAQ:TGTX	Biotechnology	4.72%
Green Cross Holdings Preference Shares KO:005257	Biotechnology	0.50%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	33.70%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Cybin Inc NEO:CYBN	Biotechnology	0.21%

Annual Asset Resilience Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Suzhou Zelgen Biopharmaceuticals Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	1.35%	CN¥40.50 Million ≈ $5.93 Million	CN¥3.00 Billion ≈ $439.67 Million	-3.40pp
2023-12-31	4.75%	CN¥137.02 Million ≈ $20.05 Million	CN¥2.89 Billion ≈ $422.49 Million	-10.18pp
2022-12-31	14.92%	CN¥248.93 Million ≈ $36.43 Million	CN¥1.67 Billion ≈ $244.13 Million	+11.18pp
2021-12-31	3.74%	CN¥65.26 Million ≈ $9.55 Million	CN¥1.75 Billion ≈ $255.49 Million	-19.09pp
2020-12-31	22.83%	CN¥449.85 Million ≈ $65.83 Million	CN¥1.97 Billion ≈ $288.31 Million	+20.96pp
2019-12-31	1.87%	CN¥6.00 Million ≈ $877.99K	CN¥320.27 Million ≈ $46.87 Million	--

pp = percentage points

About Suzhou Zelgen Biopharmaceuticals Co Ltd

SHG:688266 China Biotechnology

Market Cap

$4.35 Billion

CN¥29.71 Billion CNY

Market Cap Rank

#3914 Global

#571 in China

Share Price

CN¥112.22

Change (1 day)

+1.69%

52-Week Range

CN¥75.75 - CN¥147.40

All Time High

CN¥147.40